Puerarin alleviates cognitive impairment and oxidative stress in APP/PS1 transgenic mice

International Journal of Neuropsychopharmacology

Volumn 17, Issue 4, 2014, Pages 635-644

  Zhou, Yanyan ^a   Xie, Ning ^a   Li, Libo ^b   Zou, Yu ^b   Zhang, Xiaojie ^b   Dong, Miaoxian ^b  

^a HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; APP PS1 transgenic mice; cognitive impairment; glycogen synthase kinase 3 ; puerarin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PRESENILIN 1; PROTEIN KINASE B; PUERARIN; TRANSCRIPTION FACTOR NRF2; WATER; GLYCOGEN SYNTHASE KINASE 3; ISOFLAVONE DERIVATIVE; PRESENILIN 1, MOUSE; VASODILATOR AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME LOCALIZATION; HIPPOCAMPUS; LEARNING; LIPID PEROXIDATION; MALE; MAZE TEST; MENTAL PERFORMANCE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPATIAL MEMORY; TREATMENT DURATION; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; ISOFLAVONES; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; PRESENILIN-1; VASODILATOR AGENTS;

EID: 84896404312     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571300148X     Document Type: Article

References (53)

1. Abdul HM, Sultana R, St Clair DK, Markesbery WR, Butterfield DA (2008) Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic Biol Med 45:1420-1425.
2. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, Youdim MB (2007) Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4:403-411.
3. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, Butterfield DA (2012) Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52:2292-2301.
4. Block ML (2008) NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 9(Suppl. 2):S8. doi: 10.1186/1471-2202-9-S2-S8.
5. Butterfield DA (1997) beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10:495-506.
6. Choi H, Park HH, Koh SH, Choi NY, Yu HJ, Park J, Lee YJ, Lee KY (2012) Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. Neurotoxicol 33:85-90.
7. Choudhry F, Howlett DR, Richardson JC, Francis PT, Williams RJ (2012) Pro-oxidant diet enhances β/γ secretase-mediated APP processing in APP/PS1 transgenic mice. Neurobiol Aging 33:960-968.
8. Coomaraswamy J, Kilger E, Wölfing H, Schäfer C, Kaeser SA, Wegenast-Braun BM, Hefendehl JK, Wolburg H, Mazzella M, Ghiso J, Goedert M, Akiyama H, Garcia-Sierra F, Wolfer DP, Mathews PM, Jucker M (2010) Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci USA 107:7969-7974.
9. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, Frey WH (2010) Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 13:195-201.
10. Du B, Ohmichi M, Takahashi K, Kawagoe J, Ohshima C, Igarashi H, Mori-Abe A, Saitoh M, Ohta T, Ohishi A, Doshida M, Tezuka N, Takahashi T, Kurachi H (2004) Both oestrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in oestrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade. J Endocrinol 183:605-615.
11. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, Lin MT (2009) Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 23:2459-2466.
12. Eftekharzadeh B, Maghsoudi N, Khodagholi F (2010) Stabilization of transcription factor Nrf2 by tBHQ prevents oxidative stress-induced amyloid beta formation in NT2N neurons. Biochimie 92:245-253.
13. Egea J, Rosa AO, Cuadrado A, García AG, López MG (2007) Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. J Neurochem 102:1842-1852.
14. Fang L, Gou S, Fang X, Cheng L, Fleck C (2013) Current progresses of novel natural products and their derivatives/analogs as anti-Alzheimer candidates: an update. Mini Rev Med Chem 13:870-887.
15. Gallagher JJ, Minogue AM, Lynch MA (2013) Impaired performance of female APP/PS1 mice in the Morris water maze is coupled with increased Aβ accumulation and microglial activation. Neurodegener Dis 11:33-41.
16. Gutierrez-Zepeda A, Santell R, Wu Z, Brown M, Wu Y, Khan I, Link CD, Zhao B, Luo Y (2005) Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci 6:54.
17. Hamilton A, Holscher C (2012) The effect of ageing on neuro-genesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. Brain Res 1449:83-93.
18. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3 beta. Proc Natl Acad Sci USA 100:6370-6375.
19. Huang HC, Xu K, Jiang ZF (2012) Curcumin-mediated neuroprotection against amyloid-β-induced mitochondrial dysfunction involves the inhibition of GSK-3β. J Alzheimers Dis 32:981-996.
20. Hui Y, Wang D, Li W, Zhang L, Jin J, Ma N, Zhou L, Nakajima O, Zhao W, Gao X (2011) Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation. J Alzheimers Dis 26:299-313.
21. Kamalvand G, Pinard G, Ali-Khan Z (2003) Heme-oxygenase-1 response, a marker of oxidative stress, in a mouse model of AA amyloidosis. Amyloid 10:151-159.
22. Kanninen K, Malm TM, Jyrkkänen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H, Yamamoto M, Ylä-Herttuala S, Levonen AL, Koistinaho J (2008) Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci 39:302-313.
23. Kanninen K, Heikkinen R, Malm T, Rolova T, Kuhmonen S, Leinonen H, Ylä-Herttuala S, Tanila H, Levonen AL, Koistinaho M, Koistinaho J (2009) Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106:16505-16510.
24. Khodagholi F, Eftekharzadeh B, Maghsoudi N, Rezaei PF (2010) Chitosan prevents oxidative stress-induced amyloid beta formation and cytotoxicity in NT2 neurons: involvement of transcription factors Nrf2 and NF-kappaB. Mol Cell Biochem 337:39-51.
25. Lambracht-Washington D, Rosenberg RN (2013) Advances in the development of vaccines for Alzheimer's disease. Discov Med 15:319-326.
26. Li L, Li W, Jung SW, Lee YW, Kim YH (2011) Protective effects of decursin and decursinol angelate against amyloid β-protein-induced oxidative stress in the PC12 cell line: the role of Nrf2 and antioxidant enzymes. Biosci Biotechnol Biochem 75:434-442.
27. Lin F, Xie B, Cai F, Wu G (2012) Protective effect of Puerarin on β-amyloid-induced neurotoxicity in rat hippocampal neurons. Arzneimittelforschung 62:187-193.
28. Liu HL, Zhao G, Cai K, Zhao HH, Shi LD (2011) Treadmill exercise prevents decline in spatial learning and memory in APP/PS1 transgenic mice through improvement of hippo-campal long-term potentiation. Behav Brain Res 218:308-314.
29. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
30. López N, Tormo C, De Blas I, Llinares I, Alom J (2013) Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33:823-829.
31. Moreira PI, Sayre LM, Zhu X, Nunomura A, Smith MA, Perry G (2010) Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Methods Mol Biol 610:419-434.
32. Pajak B, Songin M, Strosznajder JB, Gajkowska B (2009) Alzheimer's disease genetic mutation evokes ultrastructural alterations: correlation to an intracellular Abeta deposition and the level of GSK-3beta-P(Y216) phosphorylated form. Neurotoxicol 30:581-588.
33. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, Butterfield DA (2009) Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3:682-693.
34. Prasain JK, Peng N, Acosta E, Moore R, Arabshahi A, Meezan E, Barnes S, Wyss JM (2007) Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry. Biomed Chromatogr 21:410-414.
35. Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, Tobón-Velasco JC, Devijver H, García-Mayoral MF, Van Leuven F, Hayes JD, Bertho G, Cuadrado A (2012) Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol Cell Biol 32:3486-3499.
36. Reed MN, Liu P, Kotilinek LA, Ashe KH (2010) Effect size of reference memory deficits in the Morris water maze in Tg2576 mice. Behav Brain Res 212:115-120.
37. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:1981-1991.
38. Rojo AI, Rada P, Egea J, Rosa AO, López MG, Cuadrado A (2008a) Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal cell death. Mol Cell Neurosci 39:125-132.
39. Rojo AI, Sagarra MR, Cuadrado A (2008b) GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105:192-202.
40. Schäfer M, Goodenough S, Moosmann B, Behl C (2004) Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 1005:84-89.
41. Schuessel K, Schäfer S, Bayer TA, Czech C, Pradier L, Müller-Spahn F, Müller WE, Eckert A (2005) Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis 18:89-99.
42. Sompol P, Ittarat W, Tangpong J, Chen Y, Doubinskaia I, Batinic-Haberle I, Abdul HM, Butterfield DA, St Clair DK (2008) A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience 153:120-130.
43. Sultana R, Butterfield DA (2013) Oxidative modification of brain proteins in Alzheimer's disease: perspective on future studies based on results of redox proteomics studies. J Alzheimers Dis 1:243-251.
44. Texel SJ, Mattson MP (2011) Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer's disease. Antioxid Redox Signal 14:1519-1534.
45. von Otter M, Landgren S, Nilsson S, Zetterberg M, Celojevic D, Bergström P, Minthon L, Bogdanovic N, Andreasen N, Gustafson DR, Skoog I, Wallin A, Tasa G, Blennow K, Nilsson M, Hammarsten O, Zetterberg H (2010) Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech Ageing Dev 131:105-110.
46. Wan L, Nie G, Zhang J, Luo Y, Zhang P, Zhang Z, Zhao B (2011) β-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med 50:122-129.
47. Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K (2009) Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers. J Am Geriatr Soc 57:686-690.
48. Wu H, Lu C, Zhou A, Min Z, Zhang Y (2009) Enhanced oral bioavailability of puerarin using microemulsion vehicle. Drug Dev Ind Pharm 35:138-144.
49. Xu XH, Zhao TQ (2002) Effects of puerarin on D-galactose-induced memory deficits in mice. Acta Pharmacol Sin 23:587-590.
50. Yao M, Nguyen TV, Pike CJ (2007) Oestrogen regulates Bcl-w and Bim expression: role in protection against beta-amyloid peptide-induced neuronal death. J Neurosci 27:1422-1433.
51. Yu Y, He J, Zhang Y, Luo H, Zhu S, Yang Y, Zhao T, Wu J, Huang Y, Kong J, Tan Q, Li XM (2009) Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus 19:1247-1253.
52. Zhang HY, Liu YH, Wang HQ, Xu JH, Hu HT (2008) Puerarin protects PC12 cells against beta-amyloid-induced cell injury. Cell Biol Int 32:1230-1237.
53. Zou Y, Hong B, Fan L, Zhou L, Liu Y, Wu Q, Zhang X, Dong M (2013) Protective effect of puerarin against beta-amyloid-induced oxidative stress in neuronal cultures from rat hippocampus: involvement of the GSK-3β/Nrf2 signaling pathway. Free Radic Res 47:55-63.